Kinaxo Biotechnologies and Bayer Vital Collaborate on Biomarker Identification
- Posted on 05 November 2009
Kinaxo Biotechnologies and Bayer Vital have announced a collaboration. The former will apply its quantitative phosphoproteomics technology PhosphoScout for the identification of novel biomarkers in a clinical trial conducted by the latter.
Accompanying a clinical trial for the multi-kinase inhibitor Nexavar in Acute Myeloid Leukemia (AML), Kinaxo will apply its phosphoproteomics technology to reveal the drug’s influence on cellular phosphorylation patterns and to search for novel predictive biomarkers.
Furthermore, quantitative phosphoproteomics will be applied to investigate the molecular efficiency of potential combination therapies in which Nexavar will be administered together with other targeted drugs to effectively fight cancer. In turn, individualized therapeutic strategies could then improve overall treatment outcome for malignant diseases, such as AML.
